Treatment Options and the Research Horizon

Currently, there is no cure for LGMDR1 (calpainopathy). Because of this, the “standard of care” focuses on supportive management—a proactive approach to maintaining your current strength, managing symptoms, and preventing complications ^[1][2].

Physical Therapy: Proceed with Caution

Physical therapy (PT) is a cornerstone of managing LGMDR1, but it must be approached with specialized care. Because the calpain-3 protein is missing, your muscles cannot repair themselves as easily as a healthy person’s muscles ^[3].

• The Goal: Focus on maintaining mobility, flexibility, and overall cardiovascular health without overtaxing the muscles ^[4].
• The Warning on “Eccentric” Exercise: You should avoid heavy eccentric exercises—movements where the muscle lengthens under tension, such as walking downhill, slowly lowering a heavy weight, or descending stairs repeatedly ^[4][5]. These movements cause the most microscopic damage to muscle fibers, which LGMDR1 muscles struggle to fix.
• Supervision is Key: Any resistance training or new exercise routine should be strictly supervised by a therapist who understands muscular dystrophy to prevent overwork weakness ^[4].
• Stretching: Daily gentle stretching is vital to manage and prevent joint contractures (shortening of muscles or tendons), particularly at the ankles and spine ^[6].

Monitoring Your Health

While LGMDR1 primarily affects the muscles you use for movement, comprehensive care involves watching other systems:

• Respiratory Care: The muscles that help you breathe can weaken over time. Regular monitoring of your breathing (pulmonary function tests) is essential, even if you are still able to walk ^[7][8].
• Cardiac Care: Although heart involvement is rare in LGMDR1, occasional cardiac check-ups are often included in standard limb-girdle dystrophy care as a precaution ^[7].

The Research Pipeline

While most treatments are still in the early stages of research, several promising avenues are being explored:

1. Gene Therapy (AAV): Scientists are testing the use of a harmless virus (Adeno-Associated Virus or AAV) to deliver a healthy copy of the CAPN3 gene directly into muscle cells ^[9]. Preclinical studies in animals have shown that this can restore some muscle function ^[10].
2. GSK-3β Inhibitors: Researchers are looking at drugs that block a protein called GSK-3β. In lab studies, inhibiting this protein helped restore certain cellular functions that are lost when calpain-3 is missing ^[11].
3. Mitochondrial Support: Some research is looking at ways to improve the “power plants” of the cell (mitochondria), which may help muscles function better despite the calpain-3 deficiency ^[12].

Clinical Trials and Natural History

Before a new drug can be approved, researchers must understand exactly how LGMDR1 progresses over time. This is why natural history studies (like NCT05989620) are so important [NCT05989620]. These studies do not test a new drug, but they collect the data needed to design successful clinical trials in the future. Participation in these studies often makes you a “trial-ready” candidate for when interventional therapies become available [NCT05989620].